• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep Med . Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions

tetano

Editor, Senior Moderator
Cell Rep Med


. 2021 May 21;100313.
doi: 10.1016/j.xcrm.2021.100313. Online ahead of print.
Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions


Andrea R Shiakolas[SUP] 1 2 [/SUP], Kevin J Kramer[SUP] 1 2 [/SUP], Daniel Wrapp[SUP] 3 [/SUP], Simone I Richardson[SUP] 4 [/SUP], Alexandra Schäfer[SUP] 5 [/SUP], Steven Wall[SUP] 1 [/SUP], Nianshuang Wang[SUP] 3 [/SUP], Katarzyna Janowska[SUP] 6 [/SUP], Kelsey A Pilewski[SUP] 1 2 [/SUP], Rohit Venkat[SUP] 1 7 [/SUP], Robert Parks[SUP] 8 [/SUP], Nelia P Manamela[SUP] 4 [/SUP], Nagarajan Raju[SUP] 1 2 [/SUP], Emilee Friedman Fechter[SUP] 1 [/SUP], Clinton M Holt[SUP] 1 7 [/SUP], Naveenchandra Suryadevara[SUP] 1 [/SUP], Rita E Chen[SUP] 9 10 [/SUP], David R Martinez[SUP] 5 [/SUP], Rachel S Nargi[SUP] 1 [/SUP], Rachel E Sutton[SUP] 1 [/SUP], Julie E Ledgerwood[SUP] 11 [/SUP], Barney S Graham[SUP] 11 [/SUP], Michael S Diamond[SUP] 9 10 12 [/SUP], Barton F Haynes[SUP] 8 [/SUP], Priyamvada Acharya[SUP] 6 8 [/SUP], Robert H Carnahan[SUP] 1 13 [/SUP], James E Crowe Jr[SUP] 1 13 [/SUP], Ralph S Baric[SUP] 5 [/SUP], Lynn Morris[SUP] 4 [/SUP], Jason S McLellan[SUP] 3 [/SUP], Ivelin S Georgiev[SUP] 1 2 14 15 16 17 [/SUP]



Affiliations
Free PMC article

Abstract

The continual emergence of novel coronavirus (CoV) strains, like SARS-CoV-2, highlights the critical need for broadly reactive therapeutics and vaccines against this family of viruses. From a recovered SARS-CoV donor sample, we identify and characterize a panel of six monoclonal antibodies that cross-react with CoV spike (S) proteins from the highly pathogenic SARS-CoV and SARS-CoV-2, and demonstrate a spectrum of reactivity against other CoV. Epitope mapping reveals that these antibodies recognize multiple epitopes on SARS-CoV-2 S, including the receptor binding domain, N-terminal domain, and S2 subunit. Functional characterization demonstrates that the antibodies mediate phagocytosis - and in some cases trogocytosis - but not neutralization in vitro. When tested in vivo in murine models, two of the antibodies demonstrate a reduction in hemorrhagic pathology in the lungs. The identification of cross-reactive epitopes recognized by functional antibodies expands the repertoire of targets for pan-coronavirus vaccine design strategies.
 
Back
Top Bottom